A Randomized Double-blind, Placebo-controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of AK120 in the Treatment of Moderate-to-severe Atopic Dermatitis (AD) in Adolescents
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs Manfidokimab (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Sponsors Akeso Biopharma
- 16 Jan 2025 New trial record